Eli Lilly, Stock
Eli Lilly (NYSE:LLY) shares snapped six straight days of losses as the stock closed 1.39% higher, at $812.76 on Friday. The ...
"Billionaire" and "successful hedge fund manager" are titles that carry significant weight on Wall Street. These and others ...
Eli Lilly (NYSE:LLY) recently announced several significant events, including promising trial results for baricitinib in ...
Novo Nordisk faces formidable challenges from Eli Lilly and new rivals, but its first-mover advantage and expanded ...
Eli Lilly’s rising fortunes tied to its weight loss and diabetes drugs led to a nine-figure payday for its top executive.
The Danish company said the average weight loss was 15.7% for the new drug, CagriSema. The expectation had been about 25%.
AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.
Roche (RHHBY) is increasing its investment into the obesity space with an up to $5.3 billion deal with Danish drugmaker ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results